UBS Reiterates Buy Rating on Neurocrine Bio. (NBIX) Following Reports of Soleno Acquisition
Tweet Send to a Friend
UBS analyst Ashwani Verma reiterated a Buy rating and $161.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
